Lumos Diagnostics Holdings Limited Entitlement Offer

Lumos Diagnostics Holdings Limited (ASX:LDX) is conducting a 1 for 1.82 accelerated non-renounceable pro rata entitlement offer of New Shares at A$0.038 per New Share to raise approximately A$10.0 million. The Retail Entitlement Offer closes at 5.00pm (AEST) on Wednesday 2 October 2024 and is lead managed and underwritten by Bell Potter Securities Limited up to a maximum aggregate amount of $6,050,000.

Executive Commentary on Entitlement Offer

The Entitlement Offer provides eligible shareholders with the opportunity to participate in the company's growth and contribute to the funding of key initiatives, including the completion of the FebriDx CLIA waiver trial in the US, product development, sales and marketing activities, and general working capital. We appreciate the support from institutional and sophisticated investors in the successful completion of the institutional component, and we look forward to the participation of retail shareholders in the upcoming retail component of the offer.

Summary of Entitlement Offer and Outlook

Lumos Diagnostics Holdings Limited has initiated an entitlement offer to raise funds for strategic initiatives, including the completion of the FebriDx CLIA waiver trial, product development, and market expansion. The company aims to address unmet needs in human health and leverage its comprehensive product portfolio to achieve successful clinical trials and commercialization. With a focus on regulatory approvals, commercial partnerships, and a strong leadership team, Lumos is positioned to pursue its corporate strategy and enhance its market presence. The announcement provides essential details for investors and stakeholders, outlining the use of proceeds, key risks, and the company's ambitions for the future.